Skip to main content

Table 2 Case-control study: preadmission statin use and risk of hospitalization for pneumonia in Denmark (1997-2009)

From: The impact of statin use on pneumonia risk and outcome: a combined population-based case-control and cohort study

Statin use Pneumonia cases
(n = 70,914)
Population controls
(n = 709,140)
Crudea OR
(95% CI)
Adjustedb OR
(95% CI)
Never 61,783 (87.1%) 630,515 (88.9%) 1.00 (reference) 1.00 (reference)
Former (>125 days before admission) 1,908 (2.7%) 14,102 (2.0%) 1.42 (1.35-1.50) 0.97 (0.91-1.02)
Current (≤125 days before admission) 7,223 (10.2%) 64,523 (9.1%) 1.17 (1.14-1.21) 0.80 (0.77-0.83)
Current (≤125 days before admission), supplementary adjusted model for 2001-2009 6,883 (13.0%) 61,450 (11.6%) 1.18 (1.15-1.21) 0.77 (0.74-0.80)
  1. aMatched for age, sex, urbanization of place of residence, and hospitalization/index date. bAdjusted for marital status, calendar period, living with small children, any recent surgical procedure, 20 different comorbidities, alcoholism-related conditions, and 18 different preadmission medications (Table 1). The supplementary model for 2001-2009 includes 53,160 pneumonia cases and 531,600 controls and is also adjusted for receipt of current year's influenza vaccine, dementia, social medicine-related consultations, application for reimbursement for chronic or terminal illness, conversational therapy, and general practitioner preventive consultations and services. CI, confidence interval; OR, odds ratio.